Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah P Symmons

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Vascular Pharmacology|September 18, 2009
Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factorsTracey E Toms, Deborah P Symmons, George D Kitas
Arthritis Research & Therapy|May 11, 2012
Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritisMarian L Burr, Sebastien Viatte, Marwan Bukhari, et al.
Annals of the Rheumatic Diseases|May 7, 2013
The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RAJakub Závada, Mark Lunt, Rebecca Davies, et al.
RMD Open|January 27, 2017
Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RAMeghna Jani, William G Dixon, Lianne Kersley-Fleet, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Vascular Pharmacology|September 18, 2009
Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factorsTracey E Toms, Deborah P Symmons, George D Kitas
Arthritis Research & Therapy|May 11, 2012
Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritisMarian L Burr, Sebastien Viatte, Marwan Bukhari, et al.
Annals of the Rheumatic Diseases|May 7, 2013
The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RAJakub Závada, Mark Lunt, Rebecca Davies, et al.
RMD Open|January 27, 2017
Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RAMeghna Jani, William G Dixon, Lianne Kersley-Fleet, et al.
Pageof 1